There are a raft of investigational products looking to move into the rapidly growing hidradenitis suppurativa market and AbbVie is hoping to grab a decent share with two assets, the anti-interleukin-1 alpha and beta monoclonal antibody lutikizumab and its anti-inflammatory blockbuster Rinvoq.
Having been the leader for years in the hidradenitis suppurativa (HS) space thanks to Humira, AbbVie Inc. is doubling down on its efforts to advance next-generation treatments for the chronic inflammatory skin condition and moving lutikizumab into Phase III trials.
The US major has announced Phase II results which show that adults with moderate to severe HS who had previously...
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too.
The Danish firm’s dermatology products have made significant strides in the past six months, leading to an upwards revision of its sales forecast for full-year 2024.
TMB-001, a topical formulation of isotretinoin, missed its primary endpoint in the ASCEND study and will not be filed for approval. Leo is turning its attention to hand eczema and dealmaking.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
